Oncology

Published early online in Cancer, the findings suggest that the expansion of coverage through the Affordable Care Act may disproportionally benefit certain patient populations.

The accelerated review, the results of which were made public 2 days prior to a vote by an FDA advisory panel on using T-Vec in melaonma, cited concerns over the design and results of a key study with the viral drug.

While brachytherapy improved progression-free survival in men with prostate cancer, compared with traditional readiotherapy, the study found that overall survival was not very different between the 2 groups.

A late afternoon session on the first day of the 2015 Community Oncology Conference was a panel discussion called, "The Pathway Conundrum: How Many Do We Need and How Restrictive?"

The survey, conducted at The University of Texas MD Anderson Cancer Center in Houston and published in the Annals of Surgery, found that half of women with cancer in 1 breast are interested in removing their healthy breast to avoid a second cancer.

Historically, people talk about pathways as if they are an answer, but they are really just one component to cancer care delivery, said Laura Long, MD, MPH, president at TheLongView, PC.

A cancer diagnosis is a very emotional experience, and besides for lifestyle issues, medications are one of the best ways to fight the disease, according to Jan Berger, MD, MJ.

The panel discussion, "Tackling Advanced Care Planning in Payment Reform: People and Politics" at the 2015 Community Oncology Conference, included a provider who is an active proponent of advanced care planning (ACP), a program director at a nonprofit health insurance company, and a healthcare consultant who until recently worked for a big health plan.

CMS wasted nearly $251 million in taxpayer dollars on infusion drugs in just 18 months by using outdated drug pricing estimates, which drove up the cost of prescription injectable drugs for an aging baby boomer population.

Avalere, partnering with the National Comprehensive Care Network, surveyed 20 cancer centers and found that 75% of respondents were covered by at least "some" of the exchange plans in their state.

Pharmaceutical companies can expect accelerated drug development by using alternate endpoints instead of the gold standard of OS and PFS for oncology molecules.

The monoclonal antibody MPDL3280A, a PD-L1 inhibitor being developed by Genentech, generated pharmacodynamic responses as measured by circulating biomarkers in phase 1a studies in patients with triple negative breast cancer.

A general session at the Community Oncology Conference, Community Oncology 2.0, Moving Forward on Payment Reform, was a panel discussion that saw participation by 2 providers and a payer.

With the rising prices of innovative oncology treatments, many of which fall under specialty pharmaceuticals, curbing the cost of care is high on the agenda of healthcare providers.

One of the challenges providers will face in the new Oncology Care Model that CMS announced earlier this year is measuring quality and meeting quality standards under, according to Patti Forest, MD, MBA, senior medical director of network quality and performance at Blue Cross Blue Shield of North Carolina.

Given the high cost of oncology medications, many specialty pharmacies have dedicated teams to help patients overcome the financial burden, said Kirby Eng, RPh, executive director of clinical oncology management services at Onco360.

Results presented at the American Association for Cancer Research Annual Meeting 2015 show the presence of a known driver of non-small cell lung cancer in small cell lung cancer, implying that promising treatments for the former may be applicable to the latter form of the disease.